Synthetic biology market seen hitting $105B by 2035

Market Research Future projects the global synthetic biology market will grow from $21.12 billion in 2025 to $105.04 billion by 2035. The forecast points to lower gene synthesis costs, AI-enabled bioengineering and government biomanufacturing spending as the main growth drivers.

Why it matters: - The synthetic biology market is moving from a niche research category into a broader industrial platform for healthcare, manufacturing and sustainability. - The forecast implies sustained demand for DNA synthesis, bioengineering software, biomanufacturing equipment and related services through 2035. - Healthcare remains the largest near-term commercial use case, with cell and gene therapy manufacturing depending on synthetic biology tools for vector design, gene construct synthesis and quality validation.

What happened: - Market Research Future projected the global synthetic biology market will rise from USD 21.12 billion in 2025 to USD 105.04 billion by 2035. - The firm said the market is expected to grow at a 17.4% compound annual growth rate during 2026-2035. - The forecast was published Aug. 31, 2026. - Thermo Fisher Scientific expanded synthetic DNA manufacturing capacity in February 2024 to serve biotechnology customers needing high-fidelity genetic constructs.

The details: - Declining gene synthesis and DNA sequencing costs are widening access to genetic engineering tools and expanding the market for synthetic DNA procurement. - AI-powered design platforms and automated biofoundries are speeding the design-build-test-learn cycle and shortening development timelines. - Government spending is reinforcing demand, including more than USD 2 billion in the U.S. Biotechnology and Biomanufacturing Initiative. - China’s 14th Five-Year Plan for the Bio-Economy includes CNY 150 billion, or about USD 21 billion, for synthetic biology. - More than 4,500 companies worldwide have committed to Science Based Targets, which is creating demand for bio-based alternatives to petrochemical feedstocks. - Within applications, healthcare leads revenue, followed by pharmaceuticals and diagnostics, with industrial biotechnology also a major segment. - Within product types, enabling products such as enzymes and cloning kits form core infrastructure, while oligonucleotides remain a substantial segment for custom DNA production, PCR, sequencing and gene editing. - Within end users, biotechnology and pharmaceutical companies represent the largest customer base, while biopharmaceutical manufacturers are expected to hold a leading share in 2025. - North America holds the dominant market position, supported by dense platform development and commercial infrastructure. - Europe is expected to grow strongly, with Germany and the United Kingdom both cited as key markets. - Asia-Pacific is projected to be the fastest-growing region, led by China, with India and Japan also expected to expand.

Between the lines: - The market thesis is less about one breakthrough and more about multiple cost and infrastructure shifts hitting at once. - AI matters because it can compress the time and cost required to design biological systems, which improves the economics of commercial deployment. - Sovereign biomanufacturing programs suggest governments now view synthetic biology as strategic industrial infrastructure, not just a research discipline. - The competitive field remains fragmented, but the largest players likely benefit from scale, capital and broader product portfolios. - Named companies in the competitive landscape include Thermo Fisher Scientific, Merck KGaA, Illumina, GenScript, Twist Bioscience, Codexis, Danaher, Eurofins Scientific, Agilent Technologies and New England Biolabs.

What’s next: - Demand is likely to grow around precision fermentation for alternative proteins, biomanufacturing reshoring and bioeconomy investment in emerging markets. - Market Research Future said alternative proteins could top USD 30 billion by 2030, supporting more use of engineered microbes in production. - The company also expects governments in the U.S., EU and Japan to keep funding domestic biomanufacturing capacity, which should extend procurement for synthetic biology tools. - By 2035, synthetic biology is expected to be a foundational technology across biotechnology-led growth, with the strongest effects in healthcare, manufacturing and sustainability.

The bottom line: - Synthetic biology is being pushed by cheaper inputs, faster AI-enabled design and public-sector industrial policy, setting up a long growth runway through 2035.